JP2004527479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004527479A5 JP2004527479A5 JP2002562358A JP2002562358A JP2004527479A5 JP 2004527479 A5 JP2004527479 A5 JP 2004527479A5 JP 2002562358 A JP2002562358 A JP 2002562358A JP 2002562358 A JP2002562358 A JP 2002562358A JP 2004527479 A5 JP2004527479 A5 JP 2004527479A5
- Authority
- JP
- Japan
- Prior art keywords
- bisphosphonate
- medicament
- medicament according
- hydrate
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 31
- 229940122361 Bisphosphonate Drugs 0.000 claims 20
- 150000004663 bisphosphonates Chemical class 0.000 claims 20
- 150000002148 esters Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 206010031264 Osteonecrosis Diseases 0.000 claims 8
- 208000002804 Osteochondritis Diseases 0.000 claims 6
- 201000009859 Osteochondrosis Diseases 0.000 claims 6
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 210000002758 humerus Anatomy 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 2
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims 2
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims 2
- 229940062527 alendronate Drugs 0.000 claims 2
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 2
- 210000000845 cartilage Anatomy 0.000 claims 2
- 229960002286 clodronic acid Drugs 0.000 claims 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 2
- 229940009626 etidronate Drugs 0.000 claims 2
- 229940015872 ibandronate Drugs 0.000 claims 2
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims 2
- 229950006971 incadronic acid Drugs 0.000 claims 2
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 claims 2
- 229950011129 minodronic acid Drugs 0.000 claims 2
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims 2
- 229950010733 neridronic acid Drugs 0.000 claims 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical group NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 2
- 229940046231 pamidronate Drugs 0.000 claims 2
- 229940089617 risedronate Drugs 0.000 claims 2
- 229940019375 tiludronate Drugs 0.000 claims 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 2
- 229960004276 zoledronic acid Drugs 0.000 claims 2
- 101150061927 BMP2 gene Proteins 0.000 claims 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 239000004606 Fillers/Extenders Substances 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims 1
- 208000027414 Legg-Calve-Perthes disease Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 101150067309 bmp4 gene Proteins 0.000 claims 1
- 210000003010 carpal bone Anatomy 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- IWLDTXOHXPDPQG-UHFFFAOYSA-L disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]-3-pyrrolidin-1-ylpropyl]phosphinate Chemical compound [Na+].[Na+].OP(=O)(O)C(P([O-])([O-])=O)(O)CCN1CCCC1 IWLDTXOHXPDPQG-UHFFFAOYSA-L 0.000 claims 1
- 229940029303 fibroblast growth factor-1 Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 210000004095 humeral head Anatomy 0.000 claims 1
- 210000001872 metatarsal bone Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000004233 talus Anatomy 0.000 claims 1
- 210000001137 tarsal bone Anatomy 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 210000002303 tibia Anatomy 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR2907A AUPR290701A0 (en) | 2001-02-06 | 2001-02-06 | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
| AUPR4187A AUPR418701A0 (en) | 2001-04-03 | 2001-04-03 | A drug for use in bone grafting |
| AUPR6654A AUPR665401A0 (en) | 2001-07-27 | 2001-07-27 | A drug and method for the treatment of osteonecrosis |
| PCT/AU2001/001616 WO2002062351A1 (en) | 2001-02-06 | 2001-12-13 | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004527479A JP2004527479A (ja) | 2004-09-09 |
| JP2004527479A5 true JP2004527479A5 (https=) | 2005-12-22 |
Family
ID=27158265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002562358A Pending JP2004527479A (ja) | 2001-02-06 | 2001-12-13 | 骨壊死の治療用および骨壊死の発症のリスクのある患者のマネージメント用医薬 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7425549B2 (https=) |
| EP (1) | EP1365769B1 (https=) |
| JP (1) | JP2004527479A (https=) |
| KR (1) | KR20030072399A (https=) |
| CN (1) | CN1233325C (https=) |
| AT (1) | ATE496624T1 (https=) |
| AU (1) | AU2002221339B2 (https=) |
| BR (1) | BR0116862A (https=) |
| CA (1) | CA2435552C (https=) |
| CY (1) | CY1111402T1 (https=) |
| CZ (1) | CZ301361B6 (https=) |
| DE (1) | DE60143964D1 (https=) |
| DK (1) | DK1365769T3 (https=) |
| HU (1) | HUP0303013A3 (https=) |
| IL (1) | IL157201A (https=) |
| MX (1) | MXPA03007029A (https=) |
| NO (1) | NO20033446L (https=) |
| NZ (1) | NZ527351A (https=) |
| PL (1) | PL361909A1 (https=) |
| SI (1) | SI1365769T1 (https=) |
| SK (1) | SK9862003A3 (https=) |
| WO (1) | WO2002062351A1 (https=) |
| ZA (1) | ZA200305890B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1365769B1 (en) * | 2001-02-06 | 2011-01-26 | The Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children) | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
| NZ528659A (en) * | 2001-04-03 | 2005-02-25 | Royal Alexandra Hosp Children | A drug for use in bone grafting |
| RU2294203C2 (ru) * | 2001-12-21 | 2007-02-27 | Дзе Проктер Энд Гэмбл Компани | Способ лечения костных нарушений |
| RU2387451C2 (ru) * | 2002-05-10 | 2010-04-27 | Ф.Хоффманн-Ля Рош Аг | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза |
| HRP20041013B1 (hr) * | 2002-12-20 | 2013-10-25 | F. Hoffmann - La Roche Ag | Formulacija visoke doze ibandronata |
| ES2275218T3 (es) | 2003-05-07 | 2007-06-01 | Osteologix A/S | Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos. |
| WO2005072747A1 (ja) * | 2004-02-02 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 骨吸収抑制剤 |
| ITMI20040218A1 (it) * | 2004-02-10 | 2004-05-10 | Abiogen Pharma Spa | Uso di neridronato sodico per promuovere la neoformazione ossea |
| US20080167513A1 (en) | 2004-02-26 | 2008-07-10 | Osteologlx A/S | Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions |
| WO2008128056A1 (en) * | 2004-10-08 | 2008-10-23 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps |
| US7687482B2 (en) * | 2006-03-17 | 2010-03-30 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods |
| US7358361B2 (en) * | 2004-10-08 | 2008-04-15 | The Board Of Trustees Of The University Of Illinois | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| WO2006050493A2 (en) * | 2004-11-03 | 2006-05-11 | The Regents Of The University Of Michigan | Biodegradable implant for intertransverse process fusion |
| US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
| US7833270B2 (en) * | 2006-05-05 | 2010-11-16 | Warsaw Orthopedic, Inc | Implant depots to deliver growth factors to treat osteoporotic bone |
| US8062364B1 (en) | 2007-04-27 | 2011-11-22 | Knee Creations, Llc | Osteoarthritis treatment and device |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| CA2769633C (en) * | 2009-07-31 | 2017-06-06 | Thar Pharma, Llc | Crystallization method and bioavailability |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| GB201200868D0 (en) * | 2012-01-19 | 2012-02-29 | Depuy Int Ltd | Bone filler composition |
| KR20190009428A (ko) * | 2013-10-25 | 2019-01-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물 |
| WO2015200032A1 (en) | 2014-06-25 | 2015-12-30 | Spine Wave, Inc. | Minimally invasive posterolateral fusion |
| CN105012995B (zh) * | 2015-06-04 | 2018-03-09 | 武汉维斯第医用科技股份有限公司 | 一种含促骨愈合药物的胶原蛋白海绵及其制备方法 |
| US9775723B2 (en) | 2015-06-16 | 2017-10-03 | Spine Wave, Inc. | Instrument and system for placing graft, implant and graft material for minimally invasive posterolateral fusion |
| KR20180102154A (ko) * | 2016-01-14 | 2018-09-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Llp2a-비스포스포네이트 화합물로 뼈괴사를 치료하는 방법 |
| WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
| AU2017204355B2 (en) | 2016-07-08 | 2021-09-09 | Mako Surgical Corp. | Scaffold for alloprosthetic composite implant |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0675723A4 (en) | 1992-12-23 | 1998-08-05 | Merck & Co Inc | THERAPY USING BISPHOSPHONATES AND STROGENS TO TREAT AND PREVENT BONE RESORPTION. |
| US5403829A (en) * | 1993-03-24 | 1995-04-04 | Leiras Oy | Use of bisphosphonates in endo-osteal bone surgery |
| US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
| US5476865A (en) * | 1994-07-06 | 1995-12-19 | Eli Lilly And Company | Methods of inhibiting bone loss |
| CN1113440A (zh) * | 1994-07-29 | 1995-12-20 | 孟照强 | 一种治疗骨伤的中药制剂及其制备方法 |
| WO1996039974A1 (en) * | 1995-06-07 | 1996-12-19 | Implex Corporation | Femoral head core channel filling prosthesis |
| US7041641B2 (en) * | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| CA2308511C (en) * | 1997-10-29 | 2016-01-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of transfected or transduced mammalian cells for treating bone pathologies |
| US6268367B1 (en) * | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
| WO2000021542A1 (en) | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for stimulating bone formation |
| KR100763064B1 (ko) * | 1999-05-21 | 2007-10-04 | 노파르티스 아게 | 제약 조성물 및 용도 |
| AUPQ232599A0 (en) * | 1999-08-19 | 1999-09-09 | Royal Alexandra Hospital For Children, The | Drug for treating fractures |
| AU781068B2 (en) * | 1999-08-19 | 2005-05-05 | Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children), The | Drug for treating fractures |
| AU6934600A (en) * | 1999-08-27 | 2001-03-26 | Board Of Regents, The University Of Texas System | Cd40 ligand and cd40 agonist compositions and methods of use |
| GB0029111D0 (en) | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| EP1365769B1 (en) * | 2001-02-06 | 2011-01-26 | The Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children) | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
| AUPR553701A0 (en) * | 2001-06-07 | 2001-07-12 | Royal Alexandra Hospital For Children, The | A device for the delivery of a drug to a fractured bone |
-
2001
- 2001-12-13 EP EP01273650A patent/EP1365769B1/en not_active Expired - Lifetime
- 2001-12-13 AT AT01273650T patent/ATE496624T1/de active
- 2001-12-13 HU HU0303013A patent/HUP0303013A3/hu unknown
- 2001-12-13 SK SK986-2003A patent/SK9862003A3/sk unknown
- 2001-12-13 US US10/470,924 patent/US7425549B2/en not_active Expired - Fee Related
- 2001-12-13 WO PCT/AU2001/001616 patent/WO2002062351A1/en not_active Ceased
- 2001-12-13 BR BR0116862-2A patent/BR0116862A/pt not_active Application Discontinuation
- 2001-12-13 PL PL36190901A patent/PL361909A1/xx not_active IP Right Cessation
- 2001-12-13 AU AU2002221339A patent/AU2002221339B2/en not_active Ceased
- 2001-12-13 KR KR10-2003-7010328A patent/KR20030072399A/ko not_active Ceased
- 2001-12-13 MX MXPA03007029A patent/MXPA03007029A/es active IP Right Grant
- 2001-12-13 NZ NZ527351A patent/NZ527351A/en not_active IP Right Cessation
- 2001-12-13 CZ CZ20032408A patent/CZ301361B6/cs not_active IP Right Cessation
- 2001-12-13 SI SI200130991T patent/SI1365769T1/sl unknown
- 2001-12-13 JP JP2002562358A patent/JP2004527479A/ja active Pending
- 2001-12-13 CA CA2435552A patent/CA2435552C/en not_active Expired - Fee Related
- 2001-12-13 DE DE60143964T patent/DE60143964D1/de not_active Expired - Lifetime
- 2001-12-13 DK DK01273650.0T patent/DK1365769T3/da active
- 2001-12-13 CN CNB018225365A patent/CN1233325C/zh not_active Expired - Fee Related
-
2003
- 2003-07-30 ZA ZA2003/05890A patent/ZA200305890B/en unknown
- 2003-07-31 IL IL157201A patent/IL157201A/en not_active IP Right Cessation
- 2003-08-04 NO NO20033446A patent/NO20033446L/no not_active Application Discontinuation
-
2008
- 2008-08-13 US US12/191,264 patent/US7612050B2/en not_active Expired - Fee Related
-
2011
- 2011-04-20 CY CY20111100406T patent/CY1111402T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004527479A5 (https=) | ||
| AU2002244520B2 (en) | A drug for use in bone grafting | |
| CA2435552A1 (en) | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis | |
| JP2004526747A5 (https=) | ||
| CN1146152A (zh) | 二膦酸盐在矫形假体移植后在抑制骨再吸收中的应用 | |
| AU2002244520A1 (en) | A drug for use in bone grafting | |
| AU2002221339A1 (en) | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis | |
| WO2002098307A1 (en) | A device for the delivery of a drug to a fractured bone | |
| JPH08510996A (ja) | 骨の手術へのビスホスホネートの使用 | |
| Morley et al. | Calcium sulphate as a drug delivery system in a deep diabetic foot infection | |
| JP7837939B2 (ja) | 人工骨膜 | |
| AU2018203249A1 (en) | Moldable formulations containing an oxysterol in an acellular tissue matrix | |
| JP2005530819A5 (https=) | ||
| MX2012012050A (es) | Metodos y composiciones para mejorar la oseointegracion de implantes. | |
| Sama et al. | High-dose alendronate uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model | |
| KR20020027562A (ko) | 골절 치료용 약제 | |
| Goytia et al. | Bisphosphonates and osteonecrosis: potential treatment or serious complication? | |
| RU2003127076A (ru) | Лекарственное средство для лечения остеонекроза для лечения пациентов с риском развития остеонекроза | |
| KR20170045193A (ko) | 뼈 골절 및 결손 치료용 조성물 및 생성물 | |
| ES2362024T3 (es) | Fármaco para el tratamiento de osteonecrosis para la gestión de pacientes con riesgo de desarrollar osteonecrosis. |